Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BioSig Technologies Inc. Issues 2019 Shareholder Letter | ||
By: Nasdaq / GlobeNewswire - 12 Feb 2019 | Back to overview list |
|
Company provides updates on recent developments and highlights plans for future growth Santa Monica, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their February 2019 letter to its shareholders, highlighting their recent uplisting to the Nasdaq Capital Market, commercialization efforts, their relationships with world renowned medical centers and strategic goals moving forward. Recent Company Highlights
“As BioSig moves towards commercialization of our proprietary PURE EP(tm) System, we believe that now is an ideal time to update investors on the recent achievements the Company has made in establishing a platform capable of sustaining long-term growth,” stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. “The Company has fortified its balance sheet, uplisted to a more senior exchange, and expanded strategic relationships with some of the most recognizable names in the medical technology sector. We are at a key inflection point in the company’s growth trajectory and anticipate that 2019 will be a very significant year for us. We are well-positioned to execute on our early commercialization strategy and improve overall shareholder value.” To view BioSig Technologies’ Shareholder Letter please visit the Company’s website. About BioSig Technologies The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. Forward-looking Statements CONTACT: Contact: Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12424 Wilshire Blvd Ste 745 Los Angeles, CA 90025 ndrapeau@biosigtech.com 310-620-9320 |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |